Mounjaro 10 mg Pen | Almasry Pharmacy

Mounjaro 10 mg Pen | Almasry Pharmacy

Description:

Mounjaro 10 mg pen (tirzepatide) is a prescription injectable medicine used for the management of type 2 diabetes and medical weight management in adults. It belongs to a new class of medicines that act as a dual GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptor agonist, helping improve blood sugar control and support clinically significant weight loss. This pre-filled subcutaneous pen is designed for once-weekly self-injection under medical supervision as an adjunct to diet and exercise.

Indications:

• Treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise:
• • As monotherapy when metformin is inappropriate due to intolerance or contraindications.
• • In combination with other antidiabetic medicinal products (e.g. metformin, SGLT2 inhibitors, insulin) when additional glycemic control is needed.
• Weight management (weight loss and weight maintenance) in adults as an adjunct to a reduced-calorie diet and increased physical activity in patients with:
• • Body mass index (BMI) ≥ 30 kg/m2 (obesity), or
• • BMI ≥ 27 kg/m2 to < 30 kg/m2 (overweight) with at least one weight-related comorbid condition such as hypertension, dyslipidaemia, obstructive sleep apnoea, cardiovascular disease, prediabetes, or type 2 diabetes mellitus.
• Helps reduce elevated fasting and postprandial blood glucose levels.
• Supports reduction in body weight and waist circumference in appropriate patients.

Active Ingredients / Key Components:

• Tirzepatide – 10 mg per pre-filled pen (10 mg/0.5 ml solution for injection).
• Each pen delivers 0.5 ml of solution for subcutaneous injection containing tirzepatide 10 mg.
• Excipients: Full excipient list is not provided in the available information (For full ingredient information, please check the product leaflet or the manufacturer’s official website.); please refer to the official package leaflet for complete composition.

Dosage & Administration / How to Use:

• Important: Dose must be individualized and prescribed by a physician. Follow your doctor’s instructions and the patient leaflet carefully.
• Starting dose: 2.5 mg tirzepatide once weekly for 4 weeks.
• Titration: After 4 weeks at 2.5 mg, increase to 5 mg once weekly. If further control is needed, the dose may be increased in 2.5 mg increments (e.g. 7.5 mg, 10 mg, 12.5 mg, 15 mg) after a minimum of 4 weeks on the current dose, as directed by the physician.
• Recommended maintenance doses: 5 mg, 10 mg, or 15 mg once weekly, according to clinical response and tolerability.
• Maximum dose: 15 mg once weekly.
• Route of administration: Subcutaneous injection only. Do not inject intramuscularly or intravenously.
• Injection sites: Abdomen, thigh, or upper arm. Rotate injection sites with each dose to reduce the risk of irritation.
• Timing: Can be administered at any time of the day, with or without food, on the same day each week.
• If a dose is missed, follow the instructions in the official leaflet or as advised by your doctor (do not double the dose).
• If used with insulin, inject Mounjaro and insulin at separate injection sites; do not mix in the same syringe.
• Carefully read the pen’s step-by-step instructions for use before the first injection. If unsure, ask a healthcare professional to demonstrate the correct technique.

Clinical Benefits:

• Provides powerful glucose-lowering effect in adults with type 2 diabetes by enhancing insulin secretion and reducing glucagon in a glucose-dependent manner.
• Supports significant and sustained weight loss when combined with a reduced-calorie diet and increased physical activity.
• Improves glycemic markers, including fasting plasma glucose and HbA1c, helping patients reach individualized glycemic targets.
• Once-weekly dosing improves treatment convenience and may enhance adherence compared with daily injectable therapies.
• Dual GIP and GLP-1 receptor agonism may offer additional metabolic benefits beyond traditional GLP-1 receptor agonists.
• May contribute to improvements in cardiometabolic risk factors such as blood pressure, lipid profile, and waist circumference (as shown in clinical studies; individual results vary).

Warnings & Contraindications:

• Mounjaro (tirzepatide) is a prescription-only medicine and must be used under the supervision of a healthcare professional.
• Not indicated for type 1 diabetes mellitus or for the treatment of diabetic ketoacidosis.
• Not a substitute for insulin in patients who require insulin.
• Use with caution in patients with a history of pancreatitis; inform your doctor if you have had pancreatitis before.
• May cause gastrointestinal side effects (nausea, vomiting, diarrhoea); dose escalation should follow medical guidance to improve tolerability.
• Risk of hypoglycaemia increases when used in combination with insulin or sulfonylureas; dose adjustment of concomitant therapy may be required.
• Patients with severe gastrointestinal disease, severe renal impairment, or severe hepatic impairment should use only under specialist advice.
• Consult your doctor before use if pregnant, planning pregnancy, or breastfeeding. Safety in pregnancy and lactation has not been fully established.
• Do not use if you are allergic to tirzepatide or any of the excipients listed in the official leaflet.
• Inform your doctor about all medications and supplements you are taking to avoid potential interactions.
• Consult your doctor before use if you have medical conditions such as pancreatitis, severe gastrointestinal disease, kidney or liver disease, cardiovascular disease, or diabetic retinopathy.
• Keep out of reach of children.
• Not intended to diagnose, treat, cure, or prevent any disease beyond its approved indications.

Side Effects:

• Common side effects: Nausea, vomiting, diarrhoea, decreased appetite, constipation, abdominal pain, indigestion. These are usually mild to moderate and may decrease over time.
• Less common side effects: Injection site reactions (redness, itching, swelling), fatigue, dizziness, belching, gastroesophageal reflux.
• Serious side effects (seek immediate medical attention): Signs of pancreatitis (severe and persistent abdominal pain, possibly radiating to the back, with or without vomiting), signs of allergic reaction (rash, itching, swelling of face/tongue/throat, severe dizziness, difficulty breathing), severe abdominal pain, persistent vomiting, or symptoms of severe dehydration.
• If you experience symptoms of hypoglycaemia (sweating, tremor, palpitations, hunger, confusion, blurred vision), especially when used with insulin or sulfonylureas, check your blood glucose and follow your doctor’s advice.
• Report any unexpected or bothersome side effects to your doctor or pharmacist.

Storage Instructions:

Store in a cool, dry place away from direct sunlight. Keep container tightly closed. Keep out of reach of children.

Specifications:

• Product type: Prescription injectable medicine for type 2 diabetes and weight management.
• Active ingredient: Tirzepatide 10 mg per 0.5 ml solution for injection.
• Form: Pre-filled subcutaneous injection pen.
• Strength: 10 mg/0.5 ml.
• Pack size: The exact number of pens per pack is not specified in the available information (For full ingredient information, please check the product leaflet or the manufacturer’s official website.); please refer to the outer carton or pharmacy listing.
• Route: Subcutaneous use only (abdomen, thigh, or upper arm).

Disclaimer:
All pharmacy products are intended for general use only and do not replace professional medical advice, diagnosis, or treatment. Always consult a healthcare provider before use. Results may vary, and no specific outcomes are guaranteed. Products are not intended to diagnose, treat, cure, or prevent any disease unless stated. Follow label instructions carefully, as misuse may cause adverse effects. Compliance with local laws is the customer’s responsibility.